LLY

1,067.84

+2.02%↑

JNJ

234.55

+1.37%↑

ABBV

216.73

+0.69%↑

UNH

387.14

+1.09%↑

AZN

187.52

-1.36%↓

LLY

1,067.84

+2.02%↑

JNJ

234.55

+1.37%↑

ABBV

216.73

+0.69%↑

UNH

387.14

+1.09%↑

AZN

187.52

-1.36%↓

LLY

1,067.84

+2.02%↑

JNJ

234.55

+1.37%↑

ABBV

216.73

+0.69%↑

UNH

387.14

+1.09%↑

AZN

187.52

-1.36%↓

LLY

1,067.84

+2.02%↑

JNJ

234.55

+1.37%↑

ABBV

216.73

+0.69%↑

UNH

387.14

+1.09%↑

AZN

187.52

-1.36%↓

LLY

1,067.84

+2.02%↑

JNJ

234.55

+1.37%↑

ABBV

216.73

+0.69%↑

UNH

387.14

+1.09%↑

AZN

187.52

-1.36%↓

Accueil・Liste d'Actions・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Fermé

SecteurSoins de santé

1.99 2.58

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.95

Max

2.04

Chiffres clés
By Trading Economics
Revenu	-3.8M -43M
BPA	-0.18
Employés	150
EBITDA	-3.9M -43M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+358.42% upside

Dividendes
By Dow Jones
Prochains Résultats	12 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-117M 670M
Ouverture précédente	-0.59
Clôture précédente	1.99

Sentiment de l'Actualité

By Acuity

50%

148 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

1.18 / 1.69 Support & Résistance

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 mai 2026, 22:48 UTC

Acquisitions, Fusions, Rachats

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mai 2026, 16:49 UTC

Résultats

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mai 2026, 16:26 UTC

Principaux Mouvements du Marché

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mai 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mai 2026, 23:37 UTC

Résultats

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mai 2026, 23:37 UTC

Résultats

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mai 2026, 23:37 UTC

Résultats

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mai 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mai 2026, 22:33 UTC

Acquisitions, Fusions, Rachats

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mai 2026, 21:53 UTC

Résultats

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mai 2026, 21:02 UTC

Résultats

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mai 2026, 20:55 UTC

Résultats

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mai 2026, 20:30 UTC

Actions en Tendance

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mai 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 mai 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mai 2026, 20:20 UTC

Résultats

Webull 1Q Adj EPS 3c >BULL

21 mai 2026, 20:20 UTC

Résultats

Webull 1Q Rev $159.9M >BULL

21 mai 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mai 2026, 20:18 UTC

Résultats

Webull 1Q Loss/Shr 4c

21 mai 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mai 2026, 18:58 UTC

Résultats

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mai 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 mai 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mai 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mai 2026, 17:01 UTC

Résultats

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mai 2026, 16:20 UTC

Market Talk

Résultats

Stellantis Targets Distant but Constructive -- Market Talk

21 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

358.42% hausse

Prévisions sur 12 Mois

Moyen 8.71 USD 358.42%

Haut 14 USD

Bas 3.85 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.18 / 1.69Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

148 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.